TY - JOUR
T1 - Non-sedative cortical EEG signatures of allopregnanolone and functional comparators
AU - Lambert, Peter M.
AU - Ni, Richard
AU - Benz, Ann
AU - Rensing, Nicholas R.
AU - Wong, Michael
AU - Zorumski, Charles F.
AU - Mennerick, Steven
N1 - Funding Information:
The work was funded by NIMH grants MH123748 (SM), MH122379 (CFZ, SM), MH126548 (PML), HD103525 (to the Washington University Intellectual and Developmental Disabilities Research Center), the Taylor Family Institute for Innovative Psychiatric Research (SM, CFZ) and the Bantly Foundation (CFZ). CFZ is a member of the Scientific Advisory Board for Sage Therapeutics and holds equity in Sage Therapeutics. Sage Therapeutics had no role in the design or interpretation of the experiments herein. The remaining authors have nothing to disclose.
Funding Information:
The authors thank Jamie Maguire (Tufts University), Adam Kepecs, Marco Pignatelli (Washington University), and members of the Taylor Family Institute for Innovative Psychiatric Research for discussion and input.
Publisher Copyright:
© 2022, The Author(s).
PY - 2023/1
Y1 - 2023/1
N2 - Neurosteroids that positively modulate GABAA receptors are among a growing list of rapidly acting antidepressants, including ketamine and psychedelics. To develop increasingly specific treatments with fewer side effects, we explored the possibility of EEG signatures in mice, which could serve as a cross-species screening tool. There are few studies of the impact of non-sedative doses of rapid antidepressants on EEG in either rodents or humans. Here we hypothesize that EEG features may separate a rapid antidepressant neurosteroid, allopregnanolone, from other GABAA positive modulators, pentobarbital and diazepam. Further, we compared the actions GABA modulators with those of ketamine, an NMDA antagonist and prototype rapid antidepressant. We examined EEG spectra during active exploration at two cortical locations and examined cross-regional and cross-frequency interactions. We found that at comparable doses, the effects of allopregnanolone, despite purported selectivity for certain GABAAR subtypes, was indistinguishable from pentobarbital during active waking exploration. The actions of diazepam had recognizable common features with allopregnanolone and pentobarbital but was also distinct, consistent with subunit selectivity of benzodiazepines. Finally, ketamine exhibited no distinguishing overlap with allopregnanolone in the parameters examined. Our results suggest that rapid antidepressants with different molecular substrates may remain separated at the level of large-scale ensemble activity, but the studies leave open the possibility of commonalities in more discrete circuits and/or in the context of a dysfunctional brain.
AB - Neurosteroids that positively modulate GABAA receptors are among a growing list of rapidly acting antidepressants, including ketamine and psychedelics. To develop increasingly specific treatments with fewer side effects, we explored the possibility of EEG signatures in mice, which could serve as a cross-species screening tool. There are few studies of the impact of non-sedative doses of rapid antidepressants on EEG in either rodents or humans. Here we hypothesize that EEG features may separate a rapid antidepressant neurosteroid, allopregnanolone, from other GABAA positive modulators, pentobarbital and diazepam. Further, we compared the actions GABA modulators with those of ketamine, an NMDA antagonist and prototype rapid antidepressant. We examined EEG spectra during active exploration at two cortical locations and examined cross-regional and cross-frequency interactions. We found that at comparable doses, the effects of allopregnanolone, despite purported selectivity for certain GABAAR subtypes, was indistinguishable from pentobarbital during active waking exploration. The actions of diazepam had recognizable common features with allopregnanolone and pentobarbital but was also distinct, consistent with subunit selectivity of benzodiazepines. Finally, ketamine exhibited no distinguishing overlap with allopregnanolone in the parameters examined. Our results suggest that rapid antidepressants with different molecular substrates may remain separated at the level of large-scale ensemble activity, but the studies leave open the possibility of commonalities in more discrete circuits and/or in the context of a dysfunctional brain.
UR - http://www.scopus.com/inward/record.url?scp=85138950733&partnerID=8YFLogxK
U2 - 10.1038/s41386-022-01450-x
DO - 10.1038/s41386-022-01450-x
M3 - Article
C2 - 36168047
AN - SCOPUS:85138950733
SN - 0893-133X
VL - 48
SP - 371
EP - 379
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 2
ER -